IgA Serological Response for the Diagnosis of Mycobacterium abscessus Infections in Patients with Cystic Fibrosis.


Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
29 06 2022
Historique:
pubmed: 19 5 2022
medline: 2 7 2022
entrez: 18 5 2022
Statut: ppublish

Résumé

The immunoglobulin A (IgA) status of cystic fibrosis (CF) patients, presenting with or without a non-tuberculous mycobacterial (NTM) infection, has to date not been fully elucidated toward two antigenic preparations previously described. We have chosen to determine the clinical values of an IgA ELISA for the diagnosis of NTM and/or Mycobacterium abscessus infections in CF patients. One hundred and 73 sera from CF patients, comprising 33 patients with M. abscessus positive cultures, and 31 non-CF healthy controls were assessed. IgA levels were evaluated by indirect ELISAs using a surface antigenic extract named TLR2eF for TLR2 positive extract and a recombinant protein, the phospholipase C (rMAB_0555 or rPLC). These assays revealed a sensitivity of 52.6% (95% CI = 35.8% to 69%) and 42.1% (95% CI = 26.3% to 59.2%) using TLR2eF and rPLC, respectively, and respective specificities of 92.6% (95% CI = 87.5% to 96.1%) and 92% (95% CI = 86.7% to 95.7%) for samples culture positive for M. abscessus. Overall sensitivity and specificity of 66.7% and 85.4%, respectively, were calculated for IgA detection in M. abscessus-culture positive CF patients, when we combine the results of the two used antigens, thus demonstrating the efficiency in detection of positive cases for these two antigens with IgA isotype. CF patients with a positive culture for M. abscessus had the highest IgA titers against TLR2eF and rPLC. The diagnosis of NTM infections, including those due to M. abscessus, can be improved by the addition of an IgA serological assay, especially when cultures, for example, are negative. Based on these promising results, a serological follow-up of a larger number of patients should be performed to determine if the IgA response may be correlated with an active/acute infection state or a very recent infection.

Identifiants

pubmed: 35583329
doi: 10.1128/spectrum.00192-22
pmc: PMC9241595
doi:

Substances chimiques

Immunoglobulin A 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0019222

Références

J Infect Dis. 2021 Jul 15;224(2):218-228
pubmed: 33905505
J Clin Microbiol. 2009 Dec;47(12):4124-8
pubmed: 19846643
Biochem J. 1990 Oct 15;271(2):285-96
pubmed: 2241915
Jpn J Infect Dis. 2017 Sep 25;70(5):582-585
pubmed: 28367886
PLoS One. 2020 Nov 30;15(11):e0242598
pubmed: 33253290
Scand J Immunol. 2013 Sep;78(3):266-74
pubmed: 23713613
Clin Vaccine Immunol. 2010 Dec;17(12):1963-9
pubmed: 20962209
J Cyst Fibros. 2022 Mar;21(2):353-360
pubmed: 34511392
Mediators Inflamm. 2015;2015:364758
pubmed: 26347586
J Clin Microbiol. 1988 Nov;26(11):2313-8
pubmed: 2466869
Clin Diagn Lab Immunol. 2004 Jan;11(1):70-6
pubmed: 14715547
Oncotarget. 2017 Jun 6;8(23):37525-37537
pubmed: 28415587
Respir Investig. 2019 Sep;57(5):410-414
pubmed: 31085120
J Inflamm Res. 2021 Jun 14;14:2497-2506
pubmed: 34163208
Annu Rev Immunol. 2003;21:177-204
pubmed: 12524384
Tuberculosis (Edinb). 2006 May-Jul;86(3-4):179-90
pubmed: 16510311
J Clin Microbiol. 2013 Aug;51(8):2747-9
pubmed: 23740728
Tuberculosis (Edinb). 2013 Mar;93(2):189-91
pubmed: 23140854
PLoS One. 2019 Jul 1;14(7):e0219255
pubmed: 31260500
Respir Res. 2020 Jun 16;21(1):153
pubmed: 32546152
Int J Mycobacteriol. 2020 Jan-Mar;9(1):76-82
pubmed: 32474493
Clin Infect Dis. 2002 Dec 1;35(11):1328-35
pubmed: 12439795
J Clin Tuberc Other Mycobact Dis. 2020 Sep 11;21:100189
pubmed: 32995571

Auteurs

Vincent Le Moigne (V)

Université Paris Saclay, UVSQ, Inserm, Infection et Inflammation, Montigny-le-Bretonneux, France.

Anne-Laure Roux (AL)

Université Paris Saclay, UVSQ, Inserm, Infection et Inflammation, Montigny-le-Bretonneux, France.
AP-HP, GHU Paris Saclay, Hôpital Ambroise Paré, Service de Microbiologie, Boulogne-Billancourt, France.

Hélène Mahoudo (H)

Université Paris Saclay, UVSQ, Inserm, Infection et Inflammation, Montigny-le-Bretonneux, France.

Gaëtan Christien (G)

Université Paris Saclay, UVSQ, Inserm, Infection et Inflammation, Montigny-le-Bretonneux, France.

Agnès Ferroni (A)

AP-HP, GHU Paris, Hôpital Necker-Enfants Malades, Service de Microbiologie, Paris, France.

Oana Dumitrescu (O)

Hospices Civils de Lyon, Hôpital de la Croix Rousse-Centre de Biologie Nord, Institut des Agents Infectieux, Laboratoire de Bactériologie, Lyon, France.
Centre International de Recherche en Infectiologie, INSERM U1111, Université de Lyon, Lyon, France.

Gérard Lina (G)

Hospices Civils de Lyon, Hôpital de la Croix Rousse-Centre de Biologie Nord, Institut des Agents Infectieux, Laboratoire de Bactériologie, Lyon, France.
Centre International de Recherche en Infectiologie, INSERM U1111, Université de Lyon, Lyon, France.

Jean-Philippe Bouchara (JP)

UNIV Angers, UNIV Brest, Groupe d'Etude des Interactions Hôte-Pathogène (GEIHP, EA 3142), SFR 4208 ICAT, CHU, Angers, France.

Patrick Plésiat (P)

Laboratoire de Bactériologie, CHRU de Besançon, UMR CNRS 6249 Chrono-Environnement, Faculté de Médecine-Pharmacie, Université de Bourgogne Franche-Comté, Besançon, France.

Jean-Louis Gaillard (JL)

Université Paris Saclay, UVSQ, Inserm, Infection et Inflammation, Montigny-le-Bretonneux, France.
AP-HP, GHU Paris Saclay, Hôpital Ambroise Paré, Service de Microbiologie, Boulogne-Billancourt, France.

Stéphane Canaan (S)

Aix-Marseille Univ, CNRS, LISM, IMM FR3479, Marseille, France.

Geneviève Héry-Arnaud (G)

Département de Bactériologie-Virologie, Hygiène et Parasitologie-Mycologie, Centre Hospitalier Universitaire (CHU) de Brest, Brest, France.
Inserm, EFS, UMR 1078, France; Génétique, Génomique fonctionnelle et Biotechnologies », GGB, Brest, France.

Jean-Louis Herrmann (JL)

Université Paris Saclay, UVSQ, Inserm, Infection et Inflammation, Montigny-le-Bretonneux, France.
AP-HP, GHU Paris Saclay, Hôpital Raymond Poincaré, Service de Microbiologie, Garches, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH